Finally, specimen analysis from a recently completed clinical trial in canine HNSCC patients and a Phase I/Ib trial in human oral squamous cell carcinoma (NCT03635164), further validate our mouse findings that tumor only SBRT can generate a systemic immune response, particularly by mounting a CD8 effector T cell response. The gene discussed is CD8A; the disease is neoplasm.